Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma - Related Studies

Alefacept in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma or Peripheral T-Cell Non-Hodgkin's Lymphoma

This study is currently recruiting participants.

Study NCT00438802. Last updated on October 29, 2008. Information provided by National Cancer Institute (NCI)

Find Related Studies by Searching for the Conditions, Interventions, and Sponsors found in this study:


1	Conditions listed in this trial
		Lymphoma

2	Additional conditions recognized in this trial
		Lymphoma, Non-Hodgkin
		Lymphoma, T-Cell
		Lymphoma, T-Cell, Cutaneous
		Mycosis Fungoides
		Sezary Syndrome

3	More general conditions related to this trial
		Immune System Diseases
		Immunoproliferative Disorders
		Lymphatic Diseases
		Lymphoproliferative Disorders
		Neoplasms
		Neoplasms by Histologic Type

4	Interventions listed in this trial
		alefacept
		flow cytometry
		pharmacological study
		polymorphism analysis

5	More general drug interventions related to this trial
		Dermatologic Agents
		Pharmacologic Actions
		Therapeutic Uses

6	Sponsors listed in this trial
		Mayo Clinic
		National Cancer Institute (NCI)